https://www.selleckchem.com/products/hrs-4642.html
The onset of narcolepsy in the 60s is very rare, and narcoleptic symptoms in our patient were likely to be caused by pembrolizumab. This case suggests that treatment with immune checkpoint inhibitors potentially causes narcolepsy in genetically predisposed patients. This case suggests that treatment with immune checkpoint inhibitors potentially causes narcolepsy in genetically predisposed patients. There are limited treatment options for patients with metastatic or recurrent cervical cancer. Platinum-based chemotherapy plus the anti-va
Curtir
Comentario
Compartilhar
